MedTrace Logo

Mechanism Study to Investigate Difference in Efficacy of Neoadjuvant Chemoimmunotherapy in Lung Squamous Cell Carcinoma

NCT06436040 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2024-05-30

No results posted yet for this study

Summary

To explore mechanisms of immunotherapy resistance and relation to changes in the TME before and after PD-1 blockade combined with chemotherapy

Conditions

  • Tumor Microenvironment
  • Lung Squamous Cell Carcinoma
  • Neoadjuvant Chemoimmunotherapy

Interventions

OTHER

Pathological response assessment

The pathological response classification in our study was based on the histopathologic examination of the surgically resected specimens reviewed by two experienced pathologists.

Sponsors & Collaborators

  • Tang-Du Hospital

    lead OTHER

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-24
Primary Completion
2024-11-16
Completion
2025-05-16

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06436040 on ClinicalTrials.gov